Standard BioTools Inc (LAB)

NASD · Healthcare · Medical Devices · USA

Standard BioTools Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.

Standard BioTools provides instrumentation, consumables, and services for biomedical research, offering platforms for mass cytometry, spatial biology imaging, and genomics analysis. The company sells solutions to academic institutions, translational research centers, and biopharmaceutical companies for applications in early discovery and clinical research. Its manufacturing operations are based in Singapore and Canada, with distribution through direct sales and distributors globally.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Standard BioTools Inc stock.

Our verdict on LAB

Undervalued: intrinsic value $0.79 per share, market price $0.54, margin of safety 31.5% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $0.79; the price of $0.54 is 31% below that value.

ETFs with the most weight in LAB

7 more funds hold it; the full list is part of the paid plan.

More on LAB

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than LAB in Medical Devices

4 more in this industry show a wider margin of safety.

Is LAB undervalued or overvalued?

LAB is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.79; the price of $0.54 is 31% below that value.

What is the intrinsic value of LAB?

$0.79 per share (as of the 2026-11-17 close), against a market price of $0.54. That is a margin of safety of 31.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.